This clinical trial is focused on studying treatments for Multiple Myeloma, a type of blood cancer that affects elderly patients who are newly diagnosed and not eligible for a transplant. The study will explore the effectiveness of a combination of medications, including Isatuximab, Lenalidomide, Dexamethasone, and possibly Bortezomib. Isatuximab is a humanized monoclonal antibody, which means it is a type of protein designed to target specific cells in the body. Lenalidomide and Dexamethasone are medications that help control the growth of cancer cells, while Bortezomib is used to prevent cancer cells from multiplying.
The purpose of this study is to evaluate the effectiveness of these treatments in reducing the presence of cancer cells in the bone marrow over a period of 18 months. Participants will receive the medications either through oral solutions, tablets, or injections, depending on the specific drug. The study will monitor the participants’ health and response to the treatment over time, with regular check-ups and assessments to ensure safety and effectiveness.
Throughout the study, researchers will collect data on various health parameters, including the rate of response to the treatment and any side effects experienced. The goal is to determine the best combination of these medications for treating Multiple Myeloma in elderly patients who are not candidates for high-dose chemotherapy and stem cell transplant. The study is expected to continue until 2026, providing valuable insights into the management of this condition.
France 
